917 |
Anti-Platelet Therapies in Cardiovascular Disease: From Stable CAD to ACS and Afib |
Roxana Mehran |
Jul. 22. 09 |
916 |
Strategic Approaches to Obtain Better and Earlier CV Outcome |
Weon Kim |
Jul. 22. 09 |
915 |
The Impact of Diabetes in the DES Long-Term Outcome |
Seung-Jung Park |
Jul. 22. 09 |
914 |
Long-Term Clinical Outcome of Sirolimus-Eluting Stent over 6 Years |
Martin Bert Leon |
Jul. 22. 09 |
913 |
Real World Experiences of 2nd Generation DES |
Ian T. Meredith |
Jul. 22. 09 |
912 |
The Latest Updates in DES Clinical Data |
Gregg W. Stone |
Jul. 22. 09 |
911 |
Does the Efficacy of Bivalirudin During PCI Depend on Clopidogrel Pretreatment? |
Matthew Price |
Jul. 22. 09 |
910 |
STEMI and NSTEMI Pharmacology Confusion: How to Choose and Use Antithrombins (Unfractionated and Low Molecular Weight Heparins, Bivalirudin, Fondaparinux) and Antiplatelet Agents (Aspirin, Clopidogrel, and Prasugrel) |
Gregg W. Stone |
Jul. 22. 09 |
909 |
Systemic Therapy for Plaque Stabilization: New Drugs Targeting LP-PLA2 |
Patrick W. Serruys |
Jul. 22. 09 |
908 |
Regional Therapy: FIH Experience of A Novel Self Expandable Nitinol Device |
Juan F. Granada |
Jul. 22. 09 |